

Paclitaxel (weekly) in combination with trastuzumab plus pertuzumab				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
NCMAG125	Paclitaxel (weekly) in combination with trastuzumab plus pertuzumab for the first-line treatment of adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who are considered fit for treatment with pertuzumab plus trastuzumab plus a taxane.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/01/2026	
Other Decision Specified : National Cancer Medicines Advisory Group (NCMAG) Programme.				
Web Link : https://www.healthcareimprovementscotland.scot/wp-content/uploads/2026/01/NCMAG-125-Advice-Document-Paclitaxel-January-2026.pdf				

marstacimab solution for injection in pre-filled pen (Hympavzi®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2759	for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with: <ul style="list-style-type: none"> • severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or • severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors. SMC restriction: severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/01/2026	17/03/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9705/marstacimab-hympavzi-final-dec-2025-amended-120126-for-website.pdf				

nivolumab concentrate for solution for infusion (Opdivo®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2820	in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high colorectal cancer in the following setting: first-line treatment of unresectable or metastatic colorectal cancer.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/01/2026	17/03/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9660/nivolumab-opdivo-final-dec-2025-for-website.pdf				
zolbetuximab powder for concentrate for solution for infusion (Vyloy®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2839	In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/01/2026	17/03/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9663/zolbetuximab-vyloy-final-dec-2025-for-website.pdf				

serplulimab concentrate for infusion (Hetronifly®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2840	in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).	Not routinely available as not recommended for use in NHS Scotland	19/01/2026	17/12/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9662/serplulimab-hetronifly-final-dec-2025-for-website.pdf				
exagamglogene autotemcel dispersion for infusion (Casgevy®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2852	for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises who have the $\beta S/\beta S$, $\beta S/\beta +$ or $\beta S/\beta 0$ genotype, for whom haematopoietic stem cell transplantation is appropriate and a human leukocyte antigen matched related haematopoietic stem cell donor is not available.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/01/2026	22/04/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9659/exagamglogene-autotemcel-casgevy-final-dec-2025-for-website.pdf				

ciclosporin 1mg/mL eye drops, solution in multi-dose container (Vevizye®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2873	treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca) in adult patients, which has not improved despite treatment with tear substitutes.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/01/2026	17/03/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9655/ciclosporin-vevizye-abb-final-dec-2025-for-website.pdf				

clascoterone cream (Winlevi®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2894	topical treatment of acne vulgaris in patients 12 years of age and older.	Not routinely available as not recommended for use in NHS Scotland	19/01/2026	17/12/2025
Other Decision Specified : Non-Submission				
Web Link : https://scottishmedicines.org.uk/media/9656/clascoterone-winlevi-non-sub-final-dec-2025-for-website.pdf				

daratumumab solution for injection (Darzalex®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2895	as monotherapy for the treatment of adult patients with smouldering multiple myeloma at high risk of developing multiple myeloma.	Not routinely available as not recommended for use in NHS Scotland	19/01/2026	17/12/2025
Other Decision Specified : Non-Submission				
Web Link : https://scottishmedicines.org.uk/media/9657/daratumumab-darzalex-non-sub-final-dec-2025-for-website.pdf				
dupilumab solution for injection in pre-filled pen and syringe (Dupixent®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2896	treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older whose disease is not adequately controlled with H1 antihistamine treatment.	Not routinely available as not recommended for use in NHS Scotland	19/01/2026	17/12/2025
Other Decision Specified : Non-Submission				
Web Link : https://scottishmedicines.org.uk/media/9658/dupilumab-dupixent-non-sub-final-dec-2025-for-website.pdf				

pirtobrutinib film-coated tablets (Jaypirca®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2897	as monotherapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.	Not routinely available as not recommended for use in NHS Scotland	19/01/2026	17/12/2025
Other Decision Specified : Non-Submission				
Web Link : https://scottishmedicines.org.uk/media/9661/pirtobrutinib-jaypirca-non-sub-final-dec-2025-for-website.pdf				